leisure time -WSS

leisure time

author：focus 2025-08-19 10:39:22 - browse：5881

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Brain technologies pose threats that are all too real, experts warn

hotspot

WSS

First medicine developed to treat MASH expected to be approved soon

AltruBio raises $225 million to develop ulcerative colitis drug

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Is it ever OK for doctors to lie to their patients?

PBM executives asked to testify by House panel

Has Bernie Sanders reached the limit of his pharma bullying effort?

hotspot

leisure time

focus

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Jerome Adams on the need for new antivirals for Covid

Brain technologies pose threats that are all too real, experts warn

Alkermes shareholders re

The drug industry has found itself all alone in Washington

Duchenne breakthrough therapy leaves behind pioneering families

Change Healthcare payments predicted restored March 15

State Dept. review finds Biden bears some blame for Afghanistan failures

Air quality improving but still lags in Black, Hispanic communities

knowledge

The drug industry has found itself all alone in Washington

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

AltruBio raises $225 million to develop ulcerative colitis drug

The creative science of coining drug names

Can gargling with Listerine treat gonorrhea of the mouth?

Brain MRIs reveal impact of 'toxic stress' on Black children

hotspot

focus

hotspot

knowledge